216 related articles for article (PubMed ID: 20530652)
1. Arg13 of B-type natriuretic Peptide reciprocally modulates binding to guanylyl cyclase but not clearance receptors.
Dickey DM; Barbieri KA; McGuirk CM; Potter LR
Mol Pharmacol; 2010 Sep; 78(3):431-5. PubMed ID: 20530652
[TBL] [Abstract][Full Text] [Related]
2. Biochemistry and physiology of the natriuretic peptide receptor guanylyl cyclases.
Tremblay J; Desjardins R; Hum D; Gutkowska J; Hamet P
Mol Cell Biochem; 2002 Jan; 230(1-2):31-47. PubMed ID: 11952095
[TBL] [Abstract][Full Text] [Related]
3. Left ventricular assist device support reverses altered cardiac expression and function of natriuretic peptides and receptors in end-stage heart failure.
Kuhn M; Voss M; Mitko D; Stypmann J; Schmid C; Kawaguchi N; Grabellus F; Baba HA
Cardiovasc Res; 2004 Nov; 64(2):308-14. PubMed ID: 15485690
[TBL] [Abstract][Full Text] [Related]
4. Pro-Atrial Natriuretic Peptide: A Novel Guanylyl Cyclase-A Receptor Activator That Goes Beyond Atrial and B-Type Natriuretic Peptides.
Ichiki T; Huntley BK; Sangaralingham SJ; Burnett JC
JACC Heart Fail; 2015 Sep; 3(9):715-23. PubMed ID: 26362447
[TBL] [Abstract][Full Text] [Related]
5. Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation.
Dickey DM; Potter LR
J Mol Cell Cardiol; 2011 Jul; 51(1):67-71. PubMed ID: 21459096
[TBL] [Abstract][Full Text] [Related]
6. The natriuretic peptides BNP and CNP increase heart rate and electrical conduction by stimulating ionic currents in the sinoatrial node and atrial myocardium following activation of guanylyl cyclase-linked natriuretic peptide receptors.
Springer J; Azer J; Hua R; Robbins C; Adamczyk A; McBoyle S; Bissell MB; Rose RA
J Mol Cell Cardiol; 2012 May; 52(5):1122-34. PubMed ID: 22326431
[TBL] [Abstract][Full Text] [Related]
7. Apparent B-type natriuretic peptide selectivity in the kidney due to differential processing.
Kishimoto I; Hamra FK; Garbers DL
Can J Physiol Pharmacol; 2001 Aug; 79(8):715-22. PubMed ID: 11558680
[TBL] [Abstract][Full Text] [Related]
8. Cardiac and intestinal natriuretic peptides: insights from genetically modified mice.
Kuhn M
Peptides; 2005 Jun; 26(6):1078-85. PubMed ID: 15911075
[TBL] [Abstract][Full Text] [Related]
9. Natriuretic peptide pathways in heart failure: further therapeutic possibilities.
Sangaralingham SJ; Kuhn M; Cannone V; Chen HH; Burnett JC
Cardiovasc Res; 2023 Feb; 118(18):3416-3433. PubMed ID: 36004816
[TBL] [Abstract][Full Text] [Related]
10. ProBNP(1-108) is resistant to degradation and activates guanylyl cyclase-A with reduced potency.
Dickey DM; Potter LR
Clin Chem; 2011 Sep; 57(9):1272-8. PubMed ID: 21768217
[TBL] [Abstract][Full Text] [Related]
11. Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases.
Potter LR
Pharmacol Ther; 2011 Apr; 130(1):71-82. PubMed ID: 21185863
[TBL] [Abstract][Full Text] [Related]
12. Molecular physiology of natriuretic peptide signalling.
Kuhn M
Basic Res Cardiol; 2004 Mar; 99(2):76-82. PubMed ID: 14963665
[TBL] [Abstract][Full Text] [Related]
13. Guanylyl cyclase / atrial natriuretic peptide receptor-A: role in the pathophysiology of cardiovascular regulation.
Pandey KN
Can J Physiol Pharmacol; 2011 Aug; 89(8):557-73. PubMed ID: 21815745
[TBL] [Abstract][Full Text] [Related]
14. Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (NPR)-B, Not NPR-A, is the predominant natriuretic peptide receptor in the failing heart.
Dickey DM; Flora DR; Bryan PM; Xu X; Chen Y; Potter LR
Endocrinology; 2007 Jul; 148(7):3518-22. PubMed ID: 17412809
[TBL] [Abstract][Full Text] [Related]
15. The natriuretic peptide/guanylyl cyclase--a system functions as a stress-responsive regulator of angiogenesis in mice.
Kuhn M; Völker K; Schwarz K; Carbajo-Lozoya J; Flögel U; Jacoby C; Stypmann J; van Eickels M; Gambaryan S; Hartmann M; Werner M; Wieland T; Schrader J; Baba HA
J Clin Invest; 2009 Jul; 119(7):2019-30. PubMed ID: 19487812
[TBL] [Abstract][Full Text] [Related]
16. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications.
Potter LR; Yoder AR; Flora DR; Antos LK; Dickey DM
Handb Exp Pharmacol; 2009; (191):341-66. PubMed ID: 19089336
[TBL] [Abstract][Full Text] [Related]
17. The guanylyl cyclase-deficient mouse defines differential pathways of natriuretic peptide signaling.
Lopez MJ; Garbers DL; Kuhn M
J Biol Chem; 1997 Sep; 272(37):23064-8. PubMed ID: 9287305
[TBL] [Abstract][Full Text] [Related]
18. Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: regulation and therapeutic implications.
Ichiki T; Schirger JA; Huntley BK; Brozovich FV; Maleszewski JJ; Sandberg SM; Sangaralingham SJ; Park SJ; Burnett JC
J Mol Cell Cardiol; 2014 Oct; 75():199-205. PubMed ID: 25117468
[TBL] [Abstract][Full Text] [Related]
19. Genetic models reveal that brain natriuretic peptide can signal through different tissue-specific receptor-mediated pathways.
Chusho H; Ogawa Y; Tamura N; Suda M; Yasoda A; Miyazawa T; Kishimoto I; Komatsu Y; Itoh H; Tanaka K; Saito Y; Garbers DL; Nakao K
Endocrinology; 2000 Oct; 141(10):3807-13. PubMed ID: 11014237
[TBL] [Abstract][Full Text] [Related]
20. Role of natriuretic peptide receptor guanylyl cyclase-A in myocardial infarction evaluated using genetically engineered mice.
Nakanishi M; Saito Y; Kishimoto I; Harada M; Kuwahara K; Takahashi N; Kawakami R; Nakagawa Y; Tanimoto K; Yasuno S; Usami S; Li Y; Adachi Y; Fukamizu A; Garbers DL; Nakao K
Hypertension; 2005 Aug; 46(2):441-7. PubMed ID: 15998711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
